Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer

NCT00995488 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

16

Enrollment

OTHER

Sponsor class

Stopped Terminated prematurely due to low accrual.

Conditions

Urothelial Cancer
Bladder Cancer

Interventions

DRUG: ABI-007 (Abraxane®)

Sponsor

University of Michigan Rogel Cancer Center

Collaborators

[object Object]